CGP 29287

Known as: CGP-29,287, CGP-29287, L-Lysine, N6-((1,1-dimethylethoxy)carbonyl)-N2-(N-(N-(3-hydroxy-6-methyl-1-oxo-4-((N-(N-(1-(N2-(N2-((phenylmethoxy)carbonyl)-L-arginyl)-L-arginyl)-L-prolyl)-L-phenylalanyl)-L-histidyl)amino)heptyl)-L-isoleucyl)-L-histidyl)-, methyl ester, (S-(R*,R*))- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1987-1994
0119871994

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
To assess the effects of inhibition of the renin-angiotensin system at different levels on plasma concentrations of components of… (More)
Is this relevant?
1991
1991
A method for the measurement of renal clearances was adapted in a novel manner to the conscious marmoset. Twenty-four hours… (More)
Is this relevant?
1988
1988
To prevent in vitro generation of angiotensins, the renin inhibitor CGP 29287 (CGP) was added to blood sampling tubes. Plasma… (More)
Is this relevant?
1988
1988
The mechanism by which monoclonal antibodies directed against human renin (R3-36-16 and R3-47-10) inhibit renin activity was… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
1987
1987
The primate-specific renin inhibitor CGP 29287 (30 mg/kg/d, n = 5) or the converting-enzyme inhibitor CGS 14831 (30 mg/kg/d, n… (More)
Is this relevant?